PharmaTelevision - GSK: Mark Wilson shares his enthusiasm about the need for challenge in the drug delivery space

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: GSK: Mark Wilson shares his enthusiasm about the need for challenge in the drug delivery space

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Mark Wilson, Director of Collaborative Management of GSK.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Issues in Formulation area

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at the LESI Conference in London 2011. On this show, I have Mark Wilson, who is the Director of Collaborative Management for pre-clinical work at GSK that pre-clinical work includes formulation, drug delivery and affiliated technologies. Welcome to the show.

Mark Wilson:

Thank you.

Fintan Walton:

Mark, you're obviously involved with LESI and the conference here, we'll talk about that in a moment, but just want to talk a little bit about your role at GSK , that role as I understand it is in the area of particularly in pre-clinical, but also in the area of formulation?

Mark Wilson:

That's correct.

Fintan Walton:

Now having watched drugs go through clinical trials and one of the big issues is formulation once you've got a drug it's important to have a good formulation sometimes those formulations have to be quite sophisticated, the question for you Mark is have we reached saturation point in terms of a number of solutions to a formulation problem?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Mark Wilson

Director

Mark Wilson is Director, Collaboration Management, Europe for the Pharmaceutical Development department of GlaxoSmithKline's pre-clinical development division. He is responsible for the licensing and collaboration activity of the formulation department of GSK , which operates globally and which employs approximately 10% of GSK 's R&D headcount. Mark has worked for SmithKline Beecham and GSK in a licensing role for the last seven years and has been involved in over 100 commercial transactions and alliances. His work for the last 18 months has been concentrated on corporate venturing activity. He originally trained as an engineer and holds a Master's degree and a doctorate in chemical engineering from the University of Leeds, in addition to an MBA from Columbia University and London Business School.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

GlaxoSmithKline

The GlaxoSmithKline together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter ( OTC) medicines, and health-related consumer products worldwide. Its principal pharmaceutical products in various therapeutic areas comprise respiratory , HIV, central nervous system , cardiovascular and urogenital , metabolic , anti-bacterials , oncology and emesis , and vaccines and dermatologicals . Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks for energy and hydration; Horlicks, a malted, milk-based drink and food for nutrition application; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.